<DOC>
	<DOCNO>NCT01048008</DOCNO>
	<brief_summary>DM-CHOC-PEN polychlorinated pyridine cholesteryl carbonate demonstrate antineoplastic activity human xenograft intracerebrally implant tumor mouse model , acceptable preclinical toxicity mouse , rat dog model ; behavioral cognitive impairment/neurotoxicities note mouse rat model . The drug ready human use soy bean oil/lecithin/glycerin water emulsion , latter document - chemically biologically stable safe . Patients currently enrol treat protocol . Patients advanced cancer , without central nervous system involvement eligible enrollment , provide require blood eligibility requirement meet .</brief_summary>
	<brief_title>Study 4-Demethylcholesteryloxycarbonylpenclomedine ( DM-CHOC-PEN ) Patients With Advanced Cancer</brief_title>
	<detailed_description>4-Demethylcholesterylpenclomedine ( DM-CHOC-PEN ) polychlorinated pyridine cholesteryl carbonate demonstrate complete remission administrate mice bearing intracranially implanted human cancer xenograft ( glioblastomas breast cancer ) acceptable preclinical toxicity profile - mouse , rat dog . The drug administer intravenously every 21 day infusion . The start dose 39 mg/M2 ( base 1/10 LD10 observe mice rat ) . A modified accelerated dose protocol Simon , Freidlin , et al process escalate dosage reduce number patient require minimize ineffective dos . The protocol result one patient cohorts 40 % dosage escalation . When 1st instance dose limit toxicity ( DLT ) [ grade - 3 4 toxicity ] observe , 2nd instance 1st course grade 2 toxicity type observe , cohort current dose level expand 3-6 patient escalation proceed 33 % increment . During entirety study , intra-patient escalation allow . This occur patient experience &lt; grade 2 toxicity exist dose , &gt; grade 2 toxicity identify exist dose DLTs note high dose level ( patient escalate dose ) . Continuation therapy - Patients experience stabilization , partial complete remission treat continue receive drug per last dose prior identify positive result every 3 week interval . Discontinuation therapy - progressive disease and/or toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>All patient must histological evidence solid malignant tumor ( hematological malignancy exclude ) convince clinical , radiographic isotopic evidence cancer , effective proven treatment exist . CNS associate tumor prefer , require . Patients must sign informed consent complies investigator/DEKKTEC policy approve Human Investigation Review Committee . All patient must project survival time least 12 week Karnofsky performance score : &gt; 60 % ( Zubrod score &gt; 2 ) . All patient must previous chemo and/or radiotherapy least three ( 3 ) week prior entrance study recover toxic effect induce treatment ( ) . Patients receive nitrosourea type drug must treatment within last six week . Measurable lesion require admittance study desirable . Age initiate limitation 18 year old . A separate pediatric study propose evaluate tolerance drug child . Gender criterion . Hematology WBC &lt; 4,000 mm3 Platelets &lt; 100,000 mm3 Liver Function If bilirubin , AST , and/or ALT &gt; ULN Renal Function Creatinine &gt; 1.5 mg % Cardiovascular Acute myocardial infarction Congestive heart failure ( NYHA criterion uncontrolled ) Clinically significant cardiac arrhythmia uncontrolled Concomitant chemotherapy radiotherapy permit . Pregnant lactating female exclude . Women childbearing age , sexual partner , must use effective contraception program . Males sexual relation woman capable child bearing must use birth control study 3months last dose study drug . Allergies egg , lecithin soy product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Brain Neoplasms , Malignant , Primary</keyword>
	<keyword>Brain Tumor , Recurrent</keyword>
	<keyword>Advanced cancer</keyword>
</DOC>